金晟,薛强,何加极

• 1:昆明医科大学附属延安医院心内科云南省心血管疾病重点实验室

摘要(Abstract)：

原发性醛固酮增多症（PA），又称Conn综合征，是由于肾上腺皮质过度分泌醛固酮所导致的一类内分泌疾病。同时PA也是导致继发性高血压的重要原因之一。因此寻找一种更有效更适合的PA治疗方法一直是研究的热点。超选择性肾上腺动脉栓塞术（SAAE）作为一种微创且被广泛接受的激素消减手术，在20世纪90年代被首次用于PA的治疗。SAAE是在影像引导下向肾上腺注射化学药物，利用其细胞毒性使组织坏死纤维化，减少醛固酮、皮质醇等激素的分泌从而达到治疗效果。近年来越来越多关于SAAE的随机对照研究证实了该种治疗方法在治疗PA方面效果显著，但同时这些研究也暴露出SAAE在PA治疗过程中的一些弊端。本文将综合阐述SAAE治疗PA的临床疗效及其研究进展，并展望未来的研究方向。

关键词(KeyWords)： 原发性醛固酮增多症;继发性高血压;超选择动脉栓塞术;影像引导

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 金晟,薛强,何加极

参考文献(References)：

• [1]Brown JM,Siddiqui M,Calhoun DA,et al.The unrecognized prevalence of primary aldosteronism:a cross-sectional study[J].Ann Intern Med,2020,173(1):10-20.DOI:10.7326/m20-0065.
• [2]Bioletto F,Bollati M,Lopez C,et al.Primary aldosteronism and resistant hypertension:a pathophysiological insight[J].Int J Mol Sci,2022,23(9):4803.DOI:10.3390/ijms23094803.
• [3] Lainscak M,Pelliccia F,Rosano G,et al.Safety profile of mineralocorticoid receptor antagonists:spironolactone and eplerenone[J].Int J Cardiol,2015,200:25-29.DOI:10.1016/j.ijcard.2015.05.127.
• [4]Fu S,Xu W,Wang T,et al.Efficacy and safety of adrenal arterial embolization for primary aldo steronism:a systematic review and meta-analysis[J].Gland Surg,2024,13(6):825-832.DOI:10.21037/gs-23-523.
• [5]Araujo-Castro M,Pascual-Corrales E,Martín Rojas P,et al.Epidemiology and diagnosis of primary aldosteronism.What have we learned from the SPAIN-ALDO registry?[J].Endocrine,2024,83(3):527-536.DOI:10.1007/s12020-023-03573-7.
• [6]祝之明,孙芳.经导管肾上腺消融治疗难治性继发性高血压[J].临床心血管病杂志,2024,40(8):595-598.DOI:10.13201/j.issn.1001-1439.2024.08.001.
• [7]Charoensri S,Turcu AF.Primary aldosteronism prevalence-an unfolding story[J].Exp Clin Endocrinol Diabetes,2023,131(7-08):394-401.DOI:10.1055/a-2066-2696.
• [8] Mullen N,Curneen J,Donlon PT,et al.Treating primary aldosteronism-induced hypertension:novel approaches and future outlooks[J].Endocr Rev,2024,45(1):125-170.DOI:10.1210/endrev/bnad026.
• [9]Inoue H,Nakajo M,Miyazono N,et al.Treatment of aldosteronoma with superselective intraarterial injection of absolute ethanol[J].Nihon Igaku Hoshasen Gakkai Zasshi,1994,54(2):154-162.
• [10]Ethier MD,Beland MD,Mayo-Smith W.Image-guided ablation of adrenal tumors[J].Tech Vasc Interv Radiol,2013,16(4):262-268.DOI:10.1053/j.tvir.2013.08.008.
• [11]祝之明.经导管肾上腺消融术治疗原发性醛固酮增多症的争议与共识[J].中华高血压杂志,2022,30(11):1004-1007.DOI:10.16439/j.issn.1673-7245.2022.11.002.
• [12] Nakamura T,Hayashi K.Accumulating evidence suggests the potential of selective adrenal artery embolization as a standard treatment for primary aldosteronism[J].Hypertens Res,2024,47(6):1744-1746.DOI:10.1038/s41440-024-01656-0.
• [13]Lai ZQ,Fu Y,Liu JW,et al.The impact of superselective adrenal artery embolization on renal function in patients with primary aldosteronism:a prospective cohort study[J].Hypertens Res,2024,47(4):944-958.DOI:10.1038/s41440-023-01503-8.
• [14]Li X,Feng R,Xiang R,et al.Bilateral superselective adrenal artery embolization for bilateral primary aldosteronism:a novel approach in an efficacy and safety proof-of-principle trial[J].Hypertens Res,2025,48(1):189-199.DOI:10.1038/s41440-024-01881-7.
• [15] Zhang H,Li Q,Liu X,et al.Adrenal artery ablation for primary aldosteronism without apparent aldosteronoma:an efficacy and safety,proof-of-principle trial[J].J Clin Hypertens(Greenwich),2020,22(9):1618-1626.DOI:10.1111/jch.13960.
• [16]Sun F,Liu X,Zhang H,et al.Catheter-based adrenal ablation:an alternative therapy for patients with aldosteroneproducing adenoma[J].Hypertens Res,2023,46(1):91-99.DOI:10.103 8/s41440-022-01034-8.
• [17]Reincke M,Bancos I,Mulatero P,et al.Diagnosis and treatment of primary aldosteronism[J].Lancet Diabetes Endocrinol,2021,9(12):876-892.DOI:10.1016/s2213-8587(21)00210-2.
• [18] Hokotate H,Inoue H,Baba Y,et al.Aldosteronomas:experience with superselective adrenal arterial embolization in 33cases[J].Radiology,2003,227(2):401-406.DOI:10.1148/radiol.2272011798.
• [19]董徽,蒋雄京,关婷,等.经皮超选择性肾上腺动脉栓塞治疗原发性醛固酮增多症[J].中华高血压杂志,2013,21(6):536-541.DOI:10.16439/j.cnki.1673-7245.2013.06.031.
• [20]Dong H,Zou Y,He J,et al.Superselective adrenal arterial embolization for idiopathic hyperaldosteronism:12-month results from a proof-of-principle trial[J].Catheter Cardiovasc Interv,2021,97(Suppl 2):976-981.DOI:10.1002/ccd.29554.
• [21]Zhou Y,Wang D,Liu Q,et al.Case report:percutaneous adrenal arterial embolization cures resistant hypertension[J].Front Cardiovasc Med,2022,9:1013426.DOI:10.3389/fcvm.2022.1013426.
• [22]Qiu J,Li N,Xiong HL,et al.Superselective adrenal arterial embolization for primary aldosteronism without lateralized aldosterone secretion:an efficacy and safety,proof-of-principle study[J].Hypertens Res,2023,46(5):1297-1310.DOI:10.103 8/s41440-023-01236-8.
• [23]Sun F,Zhang H,He H,et al.Rationality and implication of catheter-based adrenal ablation for bilateral primary aldo steronism[J].Hypertens Res,2024,47(10):2884-2894.DOI:10.1038/s41440-024-01815-3.
• [24] Zhao Z,Liu X,Zhang H,et al.Catheter-based adrenal ablation remits primary aldosteronism:a randomized medicationcontrolled trial[J].Circulation,2021,144(7):580-582.DOI:10.1161/CIRCULATIONAHA.121.054318.
• [25]Zhou Y,Liu Q,Wang X,et al.Adrenal ablation versus mineralocorticoid receptor antagonism for the treatment of primary aldosteronism:a single-center prospective cohort study[J].Am J Hypertens,2022,35(12):1014-1023.DOI:10.1093/ajh/hpac105.
• [26]Zhou Y,Wang X,Hou J,et al.A controlled trial of percutaneous adrenal arterial embolization for hypertension in patients with idiopathic hyperaldosteronism[J].Hypertens Res,2024,47(2):311-321.DOI:10.1038/s41440-023-01420-w.
• [27]Guo RQ,Li YM,Li XG.Comparison of the radiofrequency ablation versus laparoscopic adrenalectomy for aldosteroneproducing adenoma:a meta-analysis of perioperative outcomes and safety[J].Updates Surg,2021,73(4):1477-1485.DOI:10.1007/s13304-021-01069-5.
• [28]Mao M,Feng R,Khan NA,et al.Safety and efficacy of bilateral superselective adrenal arterial embolization for treatment of idiopathic hyperaldosteronism:a prospective single-center study[J].BMC Surg,2024,24(1):242.DOI:10.1186/s12893-024-02530-z.
• [29]Liu S,Wang X,Wang P.The application value of ipsilateral superselective adrenal arteriography and adrenal venography in patients with primary aldosteronism undergoing adrenal artery embolization[J].Hypertens Res,2025,48(4):1422-1427.DOI:10.10 3 8/s41440-025-02126-x.
• [30]胡铭,刘建巍,鲍如意,等.原发性醛固酮增多症的非药物治疗[J].中华高血压杂志,2020,28(10):919-922.DOI:10.16439/j.cnki.1673-7245.2020.10.006.
• [31]祝之明,赵志钢,张和轩,等.肾上腺消融术治疗原发性醛固酮增多症相关难治性高血压:技术关键与应用前景[J].中华心血管病杂志,2021,49(10):951-956.DOI:10.3760/cma.j.cn112148-20210616-00517.
• [32]Fowler AM,Burda JF,Kim SK.Adrenal artery embolization:anatomy,indications,and technical considerations[J].AJR Am J Roentgenol,2013,201(1):190-201.DOI:10.2214/ajr.12.9507.
• [33]Bruedgam D,Adolf C,Schneider H,et al.Postoperative ACTH-stimulated aldosterone predicts biochemical outcome in primary aldosteronism[J].Eur J Endocrinol,2023,189(6):611-618.DOI:10.1093/ejendo/lvad159.
• [34]Li M,Guan L,Yang L,et al.~(68)Ga-Pentixafor PET/CT for the assessment of therapeutic outcomes following superselective adrenal arterial embolization in patients with primary aldosteronism[J].EJNMMI Res,2025,15(1):5.DOI:10.1186/s13550-024-01194-3.
• [35]曾正陪,陈康.肾上腺消融术治疗原发性醛固酮增多症应慎重开展:内分泌科观点[J].中国介入心脏病学杂志,2022,30(7):508-512.DOI:10.3969/j.issn.1004-8812.2022.07.005.
• [36]Luo T,Wan J,Liu S,et al.Establishment of a scoring model for predicting clinical outcomes in patients with unilateral primary aldosteronism after superselective adrenal artery embolization[J].Ir J Med Sci,2024,193(5):2269-2279.DOI:10.1007/s11845-024-03730-5.
• [37]祝之明.经导管肾上腺消融术治疗原发性醛固酮增多症相关高血压:现状与展望[J].中国介入心脏病学杂志,2022,30(7):503-507.DOI:10.3969/j.issn.1004-8812.2022.07.004.
• [38]李鑫,常静,毛敏.超选择性肾上腺动脉栓塞术治疗原发性醛固酮增多症:研究现状与应用前景[J].中华高血压杂志,2024,32(5):441-446.DOI:10.16439/j.issn.1673-7245.2024.05.007.
• [39]祝之明,孙芳.肾上腺消融术治疗原发性醛固酮增多症的应用与展望[J].中国实用内科杂志,2024,44(8):649-652.DOI:10.19538/j.nk2024080109.